Click here to view original web page at finance.yahoo.com
CHICAGO–(BUSINESS WIRE)– — Lead compound is an oral small molecule inhibitor of tau aggregation — — The company expects clinical testing to begin in 2021 — Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer’s disease (AD) and related neurodegenerative disorders, presented preclinical […]